MedTrace Logo

Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers

NCT06800612 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-01-30

No results posted yet for this study

Summary

retrospective/prospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and side effects compared with registry studies in the medical therapy of breast and gynecologic cancers.

Conditions

Interventions

DRUG

Oncologic drugs administered for treatment of breast cancer

Data on oncologic drugs administered for treatment of breast cancer will be recorded

DRUG

Oncologic drug administered for treatment of gynecologic cancer

Data on oncologic drugs administered for treatment of gynecologic cancer will be recorded

Sponsors & Collaborators

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    lead OTHER

Principal Investigators

  • Claudio Zamagni, MD · IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant'Orsola

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-22
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06800612 on ClinicalTrials.gov